upgrade to Tier 1 to access blurred content, display up to 300 records, and unlimited CSV download
Data last updated 2024-04-28 04:05:40 -0500 US CDT
Insider Sentiment
| Company Name | Sector | Industry | Shares Outstanding(Mil) | 52-week High/Low | Period | Acq/Dsp Transaction Countb | Ids/Sec/Mkt Quantc | Acq/Dsp Shares Amountb | Acq/Dsp PctSOd |
|---|---|---|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc / Ma | Health Care | Pharmaceuticals | 258.31 |
316.4
448.4
397.5
|
3-month |
0 / 26
|
|
0 / 67740
|
0.0 / 0.0 |
| 6-month |
0 / 39
|
|
0 / 152280
|
0.0 / 0.1 |
Data last updated 2024-04-27 07:55:23 -0500 US CDT
Major Shareholders
| Shareholder | Relation | Report Date | Holding Pct | Sharesa | Shares(Previous Report Date)a | Transactions (3 month)b | Transactions (6 month)b |
|---|---|---|---|---|---|---|---|
| Boger Joshua S | Director | 2017-06-09 | 0.1% | 361899 (0.8%, NA%) | 358958 (2017-06-05) | ||
| Mueller Peter | EVP, Global R&D, CSO | 2014-06-18 | 0.1% | 170088 (0.6%, NA%) | 169088 (2014-05-16) | ||
| Kewalramani Reshma | CEO & President | 2024-02-27 | 0.1% | 136507 (-6.3%, 25.6%) | 145893 (2024-02-21) |
C: 0 / 3
S: 0 / 27330 P: NA / 399.54 |
|
| Horton Kenneth L | EVP & Chief Legal Officer | 2014-11-19 | 0.0% | 72419 (-0.5%, NA%) | 72829 (2014-11-03) | ||
| Chodakewitz Jeffrey | EVP GMDA, CMO | 2018-02-14 | 0.0% | 69663 (-6.7%, NA%) | 74785 (2018-02-08) | ||
| Sachdev Amit | EVP Chief Patient & Ext Af Off | 2024-02-27 | 0.0% | 62772 (-7.9%, -5.2%) | 68245 (2024-02-23) |
C: 0 / 4
S: 0 / 13671 P: NA / 421.97 |
C: 0 / 5
S: 0 / 13706 P: NA / 421.84 |
| Tatsis Ourania | EVP, Chief Reg. & Quality Off. | 2024-02-27 | 0.0% | 55804 (-6.1%, 14.7%) | 59467 (2024-02-23) |
C: 0 / 4
S: 0 / 1508 P: NA / 422.06 |
C: 0 / 4
S: 0 / 1508 P: NA / 422.06 |
| Wagner Charles F Jr | EVP & Chief Financial Officer | 2024-02-27 | 0.0% | 53583 (-5.7%, 22.6%) | 56892 (2024-02-21) |
C: 0 / 2
S: 0 / 6000 P: NA / 377.44 |
|
| Smith Ian F | EVP, COO | 2018-07-03 | 0.0% | 52005 (0.0%, NA%) | 52005 (2018-06-26) | ||
| Arbuckle Stuart A | EVP, COO | 2024-02-27 | 0.0% | 49831 (-16.3%, -12.0%) | 59579 (2024-02-23) |
C: 0 / 4
S: 0 / 17736 P: NA / 422.25 |
C: 0 / 5
S: 0 / 26339 P: NA / 414.66 |
| Sachs Bruce I | Director | 2023-11-08 | 0.0% | 40000 (0.0%, NA%) | 40000 (2023-07-18) |
C: 0 / 1
S: 0 / 11250 P: NA / 385.0 |
|
| Bozic Carmen | EVP and CMO | 2024-02-27 | 0.0% | 36939 (-8.1%, 26.1%) | 40248 (2024-02-21) |
C: 0 / 2
S: 0 / 11301 P: NA / 368.37 |
|
| Sanna Bastiano | EVP, Cell & Genetic Therapies | 2023-05-09 | 0.0% | 32038 (-9.2%, NA%) | 35310 (2023-05-04) | ||
| Altshuler David | EVP, Global Research and CSO | 2024-02-27 | 0.0% | 25813 (-24.0%, -19.3%) | 34022 (2024-02-23) |
C: 0 / 4
S: 0 / 14388 P: NA / 422.32 |
C: 0 / 5
S: 0 / 14407 P: NA / 422.25 |
| Atkinson Edward Morrow Iii | EVP, Chief Technical Ops. Off. | 2024-02-27 | 0.0% | 15972 (-13.6%, 15.1%) | 18509 (2024-02-23) |
C: 0 / 4
S: 0 / 3798 P: NA / 422.11 |
C: 0 / 4
S: 0 / 3798 P: NA / 422.11 |
a Total of direct and indirect accounts with percentage change comparing with (previous report, 3 months ago). The latter is NA when no change was found in the last 3 months.
Notice: Shares amount and percentage change 1) do not reflect intraday conversion and execution of derivative securities. 2) may subject to correction on amendment filing.
b Vital&Spontaneous transactions of the past 3 and 6 months, respectively. For acquisitions, code P (open market purchase), L (small acquisition), and I (at discretion of broker) are counted. For dispositions, code S (open market sell), D (sell back to issuer) and I (at discretion of broker) are counted. "C:" count of number of transactions. "S:" shares amount involved in corrresponding transactions. "P:" average per share price of the transactions (for reference only). Horizontal bar chart denotes shares amount of acquisitions and dispositions. Black thin bar is fixed size ruler for easy comparison between reporters.
c Quantile value of transaction count in b among industry peers, sector peers, and the market, respectively.
d Percentage of transaction shares amount to shares outstanding.
Notice: red exclamation mark (!) represents the reporter has Form 4 amendment filings in the latest three reports.
Non-derivative Transactions Chart
Tips: Click legend to show single series Click any bar to highlight corresponding transaction records
what is this?
Non-derivative Transactions Table
CSV download
Tips: Click legend to show single series Click any bar to highlight corresponding transaction records what is this?
|
|
|
Tips: type "code_p" to show transactions with code "P".
| Filing Date | Transaction Date | Operation Date | Original Filing | Reporter | Relation | Opr | Amounta | %(Owned)b | ‱(SO)c | Avg Prcd | Account | Type | Full Name | Code | Remain | Shares Outstanding (Million)e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-04-03 | 2024-04-01 | 2024-04-01 to 2024-04-02 | 4 | Ambrose Kristen | SVP & CHIEF ACCOUNTING OFFICER | dsp | 465.0 | 5.84 | 0.02 | 418.56 | Direct | Common Stock | VERTEX PHARMACEUTICALS INC / MA | code F S | 7500.0
|
258.31 (VRTX) |
| 2024-02-27 | 2024-02-23 | 2024-02-23 | 4 | Wagner Charles F Jr | EVP & CHIEF FINANCIAL OFFICER | dsp | 3309.0 | 5.82 | 0.13 | 431.79 | Direct | Common Stock | VERTEX PHARMACEUTICALS INC / MA | code F | 53583.0 | 258.31 (VRTX) |
| 2024-02-27 | 2024-02-23 | 2024-02-23 to 2024-02-26 | 4 | Altshuler David | EVP, GLOBAL RESEARCH AND CSO | dsp | 8209.0 | 24.13 | 0.32 | 428.65 | Direct | Common Stock | VERTEX PHARMACEUTICALS INC / MA | code F S | 25813.0
|
258.31 (VRTX) |
| 2024-02-27 | 2024-02-23 | 2024-02-23 | 4 | Bozic Carmen | EVP AND CMO | dsp | 3309.0 | 8.22 | 0.13 | 431.79 | Direct | Common Stock | VERTEX PHARMACEUTICALS INC / MA | code F | 36939.0 | 258.31 (VRTX) |
| 2024-02-27 | 2024-02-23 | 2024-02-23 to 2024-02-26 | 4 | Atkinson Edward Morrow Iii | EVP, CHIEF TECHNICAL OPS. OFF. | dsp | 2537.0 | 13.71 | 0.1 | 429.67 | Direct | Common Stock | VERTEX PHARMACEUTICALS INC / MA | code F S | 15972.0
|
258.31 (VRTX) |
| 2024-02-27 | 2024-02-23 | 2024-02-23 | 4 | Kewalramani Reshma | CEO & PRESIDENT | dsp | 9386.0 | 6.43 | 0.36 | 431.79 | Direct | Common Stock | VERTEX PHARMACEUTICALS INC / MA | code F | 136507.0 | 258.31 (VRTX) |
| 2024-02-27 | 2024-02-23 | 2024-02-23 to 2024-02-26 | 4 | Sachdev Amit | EVP CHIEF PATIENT & EXT AF OFF | dsp | 5473.0 | 9.0 | 0.21 | 428.45 | Direct | Common Stock | VERTEX PHARMACEUTICALS INC / MA | code F S | 55325.0
|
258.31 (VRTX) |
| 2024-02-27 | 2024-02-23 | 4 | Sachdev Amit | EVP CHIEF PATIENT & EXT AF OFF | holding | 882.0 | 0 | 0.03 | 0.0 | 401(K) | Common Stock | VERTEX PHARMACEUTICALS INC / MA | NA | 258.31 (VRTX) | ||
| 2024-02-27 | 2024-02-23 | 4 | Sachdev Amit | EVP CHIEF PATIENT & EXT AF OFF | holding | 6565.0 | 0 | 0.25 | 0.0 | Held In Trust | Common Stock | VERTEX PHARMACEUTICALS INC / MA | NA | 258.31 (VRTX) | ||
| 2024-02-27 | 2024-02-23 | 2024-02-23 to 2024-02-26 | 4 | Ambrose Kristen | SVP & CHIEF ACCOUNTING OFFICER | dsp | 1711.0 | 17.68 | 0.07 | 428.65 | Direct | Common Stock | VERTEX PHARMACEUTICALS INC / MA | code F S | 7965.0
|
258.31 (VRTX) |
| 2024-02-27 | 2024-02-23 | 2024-02-23 to 2024-02-26 | 4 | Tatsis Ourania | EVP, CHIEF REG. & QUALITY OFF. | dsp | 3663.0 | 6.16 | 0.14 | 431.2 | Direct | Common Stock | VERTEX PHARMACEUTICALS INC / MA | code F S | 55804.0
|
258.31 (VRTX) |
| 2024-02-27 | 2024-02-23 | 2024-02-23 to 2024-02-26 | 4 | Arbuckle Stuart A | EVP, COO | dsp | 9748.0 | 16.4 | 0.38 | 428.65 | Direct | Common Stock | VERTEX PHARMACEUTICALS INC / MA | code F S | 49691.0
|
258.31 (VRTX) |
| 2024-02-27 | 2024-02-23 | 4 | Arbuckle Stuart A | EVP, COO | holding | 140.0 | 0 | 0.01 | 0.0 | 401(K) | Common Stock | VERTEX PHARMACEUTICALS INC / MA | NA | 258.31 (VRTX) | ||
| 2024-02-23 | 2024-02-21 | 2024-02-21 | 4 | Arbuckle Stuart A | EVP, COO | dsp | 3603.0 | 5.72 | 0.14 | 421.77 | Direct | Common Stock | VERTEX PHARMACEUTICALS INC / MA | code S | 59439.0 | 258.31 (VRTX) |
| 2024-02-23 | 2024-02-21 | 4 | Arbuckle Stuart A | EVP, COO | holding | 140.0 | 0 | 0.01 | 0.0 | 401(K) | Common Stock | VERTEX PHARMACEUTICALS INC / MA | NA | 258.31 (VRTX) | ||
| 2024-02-23 | 2024-02-21 | 2024-02-21 | 4 | Altshuler David | EVP, GLOBAL RESEARCH AND CSO | dsp | 3002.0 | 8.11 | 0.12 | 421.77 | Direct | Common Stock | VERTEX PHARMACEUTICALS INC / MA | code S | 34022.0 | 258.31 (VRTX) |
| 2024-02-23 | 2024-02-21 | 4 | Sachdev Amit | EVP CHIEF PATIENT & EXT AF OFF | holding | 6565.0 | 0 | 0.25 | 0.0 | Held In Trust | Common Stock | VERTEX PHARMACEUTICALS INC / MA | NA | 258.31 (VRTX) | ||
| 2024-02-23 | 2024-02-21 | 4 | Sachdev Amit | EVP CHIEF PATIENT & EXT AF OFF | holding | 882.0 | 0 | 0.03 | 0.0 | 401(K) | Common Stock | VERTEX PHARMACEUTICALS INC / MA | NA | 258.31 (VRTX) | ||
| 2024-02-23 | 2024-02-21 | 2024-02-21 | 4 | Sachdev Amit | EVP CHIEF PATIENT & EXT AF OFF | dsp | 3191.0 | 4.99 | 0.12 | 421.77 | Direct | Common Stock | VERTEX PHARMACEUTICALS INC / MA | code S | 60798.0 | 258.31 (VRTX) |
| 2024-02-23 | 2024-02-21 | 2024-02-21 | 4 | Atkinson Edward Morrow Iii | EVP, CHIEF TECHNICAL OPS. OFF. | dsp | 1201.0 | 6.09 | 0.05 | 421.77 | Direct | Common Stock | VERTEX PHARMACEUTICALS INC / MA | code S | 18509.0 | 258.31 (VRTX) |
| 2024-02-23 | 2024-02-21 | 2024-02-21 | 4 | Tatsis Ourania | EVP, CHIEF REG. & QUALITY OFF. | dsp | 360.0 | 0.6 | 0.01 | 421.77 | Direct | Common Stock | VERTEX PHARMACEUTICALS INC / MA | code S | 59467.0 | 258.31 (VRTX) |
| 2024-02-21 | 2024-02-20 | 4 | Leiden Jeffrey M | EXECUTIVE CHAIRMAN | holding | 440.0 | 0 | 0.02 | 0.0 | 401(K) | Common Stock | VERTEX PHARMACEUTICALS INC / MA | NA | 258.31 (VRTX) | ||
| 2024-02-21 | 2024-02-20 | 2024-02-20 | 4 | Leiden Jeffrey M | EXECUTIVE CHAIRMAN | dsp | 4118.0 | 23.01 | 0.16 | 420.58 | Direct | Common Stock | VERTEX PHARMACEUTICALS INC / MA | code F | 13778.0 | 258.31 (VRTX) |
| 2024-02-21 | 2024-02-16 | 2024-02-16 to 2024-02-20 | 4 | Tatsis Ourania | EVP, CHIEF REG. & QUALITY OFF. | dsp | 8352.0 | 12.25 | 0.32 | 422.44 | Direct | Common Stock | VERTEX PHARMACEUTICALS INC / MA | code F S | 59827.0
|
258.31 (VRTX) |
| 2024-02-21 | 2024-02-16 | 2024-02-16 to 2024-02-20 | 4 | Sachdev Amit | EVP CHIEF PATIENT & EXT AF OFF | dsp | 10375.0 | 13.95 | 0.4 | 421.82 | Direct | Common Stock | VERTEX PHARMACEUTICALS INC / MA | code F S | 63989.0
|
258.31 (VRTX) |
| 2024-02-21 | 2024-02-16 | 4 | Sachdev Amit | EVP CHIEF PATIENT & EXT AF OFF | holding | 882.0 | 0 | 0.03 | 0.0 | 401(K) | Common Stock | VERTEX PHARMACEUTICALS INC / MA | NA | 258.31 (VRTX) | ||
| 2024-02-21 | 2024-02-16 | 4 | Sachdev Amit | EVP CHIEF PATIENT & EXT AF OFF | holding | 6565.0 | 0 | 0.25 | 0.0 | Held In Trust | Common Stock | VERTEX PHARMACEUTICALS INC / MA | NA | 258.31 (VRTX) | ||
| 2024-02-21 | 2024-02-16 | 2024-02-16 to 2024-02-20 | 4 | Bozic Carmen | EVP AND CMO | dsp | 6562.0 | 14.02 | 0.25 | 422.54 | Direct | Common Stock | VERTEX PHARMACEUTICALS INC / MA | code F | 40248.0
|
258.31 (VRTX) |
| 2024-02-21 | 2024-02-16 | 2024-02-16 to 2024-02-20 | 4 | Kewalramani Reshma | CEO & PRESIDENT | dsp | 16378.0 | 10.09 | 0.63 | 422.54 | Direct | Common Stock | VERTEX PHARMACEUTICALS INC / MA | code F | 145893.0
|
258.31 (VRTX) |
| 2024-02-21 | 2024-02-16 | 4 | Arbuckle Stuart A | EVP, COO | holding | 140.0 | 0 | 0.01 | 0.0 | 401(K) | Common Stock | VERTEX PHARMACEUTICALS INC / MA | NA | 258.31 (VRTX) |
Derivative Transactions Chart
Tips: Click legend to show single series Click any bar to highlight corresponding transaction records
what is this?
Derivative Transactions Table
Tips: Click legend to show single series Click any bar to highlight corresponding transaction records what is this?
|
|
Tips: type "code_m" to show transactions with code "M".
| Filing Date | Transaction Date | Operation Date | Original Filing | Reporter | Relation | Opr | Amounta | %(Owned)b | ‱(SO)c | Avg Prcd | Account | Type | Full Name | Code | Remain | Shares Outstanding (Million)e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-04-17 | 2024-04-15 | 2024-04-15 | 4 | Sachs Bruce I | DIRECTOR | acq | 109.49 | 0.74 | 0.0 | 399.58 | Direct | Deferred Stock Units | VERTEX PHARMACEUTICALS INC / MA | code A | 14853.748 | 258.31 (VRTX) |
| 2024-01-17 | 2024-01-12 | 2024-01-12 | 4 | Sachs Bruce I | DIRECTOR | acq | 101.042 | 0.69 | 0.0 | 432.99 | Direct | Deferred Stock Units | VERTEX PHARMACEUTICALS INC / MA | code A | 14744.258 | 257.68 (VRTX) |
| 2024-01-17 | 2024-01-12 | 2024-01-12 | 4 | Mckenzie Diana | DIRECTOR | acq | 76.503 | 1.59 | 0.0 | 432.99 | Direct | Deferred Stock Units | VERTEX PHARMACEUTICALS INC / MA | code A | 4822.483 | 257.68 (VRTX) |
| 2023-12-19 | 2023-12-15 | 2023-12-15 | 4 | Kewalramani Reshma | CEO & PRESIDENT | dsp | 17135.0 | 91.63 | 0.66 | 181.83 | Direct | Stock Option (Right To Buy) | VERTEX PHARMACEUTICALS INC / MA | code M | 1565.0
|
257.68 (VRTX) |
| 2023-12-15 | 2023-12-13 | 2023-12-13 | 4 | Arbuckle Stuart A | EVP, COO | dsp | 8603.0 | 100.0 | 0.33 | 187.53 | Direct | Stock Option (Right To Buy) | VERTEX PHARMACEUTICALS INC / MA | code M | 0.0 | 257.68 (VRTX) |
| 2023-11-08 | 2023-11-06 | 2023-11-06 | 4 | Sachs Bruce I | DIRECTOR | dsp | 11250.0 | 50.0 | 0.44 | 127.54 | Direct | Stock Option (Right To Buy) | VERTEX PHARMACEUTICALS INC / MA | code M | 11250.0 | 257.68 (VRTX) |
Form 3 CSV download
| Filing Date | Date requiring statement | Form Type | Reporter | Relation | Amounta | ‱(SO)c | Avg Excercisable Prcd | Account | Type | Full Name | Shares Outstanding (Million)e |
|---|
a Sum of same type of securities in the form
b Relative to reporter's shares owned before (disposition) or after (acquisition) operation
c Relative to issuer's shares outstanding (1/10000)
d Average price for securities of the same type. Check the original form for detailed prices of multiple transactions
e Documented shares outstanding closest to the transaction date
Note: Corporate may change mapped CIK when merge or spin-off happen. Please report error if the ticker you searched for does not have up-to-date insider trading information.
Show up to 30 records per table for current tier. (Access Guide)